MicroPort Scientific : ® Broadcasts a Live Case of Firesorb® in EuroPCR

Paris, France - On May 16, a live case using Firesorb Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ('Firesorb'), the second-generation fully bioresorbable scaffold in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ('MicroPort'), was transmitted at EuroPCR in Paris. Meanwhile, MicroPort released the one-year clinical and angiographic follow-up data of FUTURE I Trial, which attracted wide attention from the attendees.

On May 17, a live case of Firesorb was broadcasted in EuroPCR 2017 Theatre Bordeaux. Professor Keifei Dou of Fuwai Hospital of Chinese Academy of Medical Sciences and his team implanted Firesorb with assistance of OCT in treating LAD diagonal artery bifurcation lesion. The patient is a 58-year-old female with unstable angina. Based on OCT and QFR result of the patient, Professor Dou decided to use Provisional Stenting strategy. During the operation, Professor Dou respectively used semi-compliant balloon and non-compliant balloon to pre-dilate the lesion and successfully implanted a 3.25*18mm Firesorb in the LAD, and then used 3.75mm non-compliant balloon to post-dilate the scaffold with assistance of OCT. Professor Dou emphasized the concept of optimizing stent implantation under the guidance of intravascular imaging including choosing the appropriate stent size, assessing and protecting the branch, fully post-dilating to make sure there is no stent malapposition. After the operation, the team had hot discussion with the experts of presidium and the attendees regarding the positioning and the visuality of the device in the X-ray and the degradation of BRS. The OCT result showed there is no malapposition with Firesorb and the operation achieved successful outcome. The presidium experts from France, Malaysia, India and Singapore fully recognized the Firesorb features such as its thin wall thickness and excellent stent expansion performance. The President of EuroPCR Jean Fajadet spoke highly of this live case, which once again demonstrated the outstanding innovative ability of the domestically developed medical devices to global cardiovascular interventional specialists.

On May 16, Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences released the one-year clinical and angiographic follow-up results of FUTURE I (angiographic, IVUS, and OCT findings). FUTURE-I Trial enrolled 45 patients. The primary endpoint is 30-day target lesion failure ('TLF'), including cardiac death, myocardial infarction of target vessel and ischemia-driven TLR (Target lesion Revascularization). The one-year clinical results showed that the occurrence of TLF is zero, the occurrence of patient-oriented composite endpoint ('PoCE') is 2.2%, and there is no death and ARC (Academic Research Consortium) defined stent thrombosis. The one-year in-device late lumen loss is 0.17±0.13mm and no restenosis occurred. The one-year clinical, angiographic, IVUS, and OCT results once again demonstrated Firesorb's feasibility, safety and efficacy in the treatment of single de novo lesions.

The Pivotal Clinical Study of Firesorb FUTURE I Trial was launched in March and FUTURE III Clinical Trial is expected to be launched in the fourth quarter of 2017. The FUTURE series clinical trials will lay a great foundation for the following clinical studies of Firesorb and the results of these clinical studies would provide evidence to support Firesorb's market launch in China.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation